JP-CSPC@EC2611A

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

Jiayi Group's BD Project MAT2A Inhibitor Downgraded by BeiGene

Jade Pharmaceutical Group Develops Online Infrared Spectroscopy Technology for Oligonucleotide Solid-Phase Deprotection Process

Huitianfu Fund Management Co. Increased Its Holdings in CSPC Group

Ji Pharmacy Group's Amphotericin B Liposome Injection Approved in the EU

Stone Pharmaceutical's Antibody-Drug Conjugate SYS6051 Approved for Clinical Trials in US and China

Sino Pharm Group Releases 2025 Annual Report

CNS Pharma Revenue Grows 40.82% in Q1 2026, Net Loss Expands by 248.88%

Sino-Pharma Group's New Drug SYH2095 Receives FDA Approval for Clinical Trials

Sino Pharm HB1901 phase Ib/III trial for advanced malignant PEComa reaches primary endpoint

Jade Pharmaceutical Group Obtained NMPA Approval to Start Clinical Trials for SYS6051

Conerna Pharmaceutical-B and Stone Pharmaceutical Affiliate Reach Phase III Clinical Endpoint for HER2-Positive Breast Cancer Neoadjuvant Therapy

CMBI Raises Target Price for Stonepharm to HKD 8.7

CMBI Adjusts Profit Forecast and Target Price for Stone Pharmaceutical Group

ZTE Entertainment and Stone Pharmaceutical Group Announce Latest Shareholder Rights Disclosure

Jefferies Analyst Maintains Sell Rating on Stone Pharmaceutical Group

Jefferies Releases Report: Stone Pharmaceutical Group's 2022 Performance Under Pressure, Target Price Increased but 'Underperform' Rating Maintained

Citi Maintains Buy Rating for Stone Pharmaceutical Group but Cuts Target Price

Jade Pharmaceutical Group Discloses 2025 Annual Report with Revenue Growth

CSPC PHARMA released FY2025 Q4 earnings on March 25 During-Market (BJT), forecast revenue HKD 9.273 B, forecast EPS HKD 0.1543

RADIANCE HLDGS

ANCHORSTONE

RIVERINE CHINA

REACH NEW HLDGS

FINELAND LIVING

NUR HOLDINGS

GOLDEN LEAF INT

UBOT HOLDING

MAN YUE TECH

01093

CONCORD HC GPannounced a proposal to issue HKD68 million in convertible bonds to a subsidiary of CSPC PHARMA. After expenses, net proceeds are expected to be around HKD63.1 million. Approximately 70% of the funds will be used to repay loans, while 30% will support working capital. The bonds will convert into 40 million H shares, equating to about 4.86% of the enlarged total issued shares.

AASTOCKS News

CSPC PHARMA

CONCORD HC GP

CONCORD HC GP  Proposes to Issue HKD68 Million Convertible Bonds to CSPC PHARMA

CSPC Pharmaceutical Group has received FDA approval for its SYS6051 antibody-drug conjugate, allowing clinical trials in the U.S. It also secured clearance from China's National Medical Products Administration for trials in advanced solid tumors. Preclinical studies indicate strong anti-tumor activity, enhancing CSPC's oncology pipeline and competitive position. Analysts rate the stock (HK:1093) as a Buy with a price target of HK$13.05. CSPC focuses on innovative therapies and operates globally, listed on the Hong Kong Stock Exchange with a market cap of HK$101.3B.

Tip Ranks

CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate

520690

159837

513120

159570

516500

513700

512290

520880

520500

588130

159316

159849

512010

562050

510660

CSPC Pharmaceutical Group reported a 40.82% year-on-year revenue increase to RMB 664.6 million for Q1 2026, but its net loss deepened to RMB 93.9 million. The company cautioned that these figures are unaudited and pertain only to its subsidiary, CSPC Innovation Pharmaceutical. Despite stable total assets, profitability metrics worsened, indicating potential cost pressures. Analysts maintain a Buy rating on the stock (HK:1093) with a price target of HK$13.05.

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Guotai CSI Bio-medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

CSPC Innovation

CSPC Innovation Posts Strong Revenue Growth but Wider Losses in Q1 2026

09995

688331

300765

China's pharmaceutical industry is rapidly evolving, with major companies like CSPC Pharmaceutical and RemeGen securing significant out-licensing agreements. The shift from low-cost manufacturing to high-value innovation is evident, particularly with the integration of AI in drug discovery. AI is compressing preclinical timelines and enhancing R&D capabilities. China now accounts for 30% of the global experimental drug pipeline and is a leader in antibody-drug conjugate projects. This growth has raised concerns among US lawmakers about China's potential dominance in the global pharmaceutical supply chain.

SCMP

REMEGEN

RemeGen

China’s drug makers are speeding up – will AI be their secret weapon?

CSPC Wins Shareholder Approval for Disposal of 30% Stake in Beijing Guoxin Huijin

CSPC Wins Shareholder Approval for Disposal of 30% Stake in Beijing Guoxin Huijin

06869

01347

06809

02513

01072

01177

01171

00883

06990

YOFC(06869) rose 18.94%, with a trading turnover 6.8 Billion HKD, and a year-to-date rose 334.8%. HUA HONG SEMI(01347) rose 14.68%, with a trading turnover 3.2 Billion HKD, and a year-to-date rose 22.5%. SBP GROUP(01177) fell 4.58%, with a trading turnover 848.3 Million HKD, and a year-to-date fell 2.3%. CSPC PHARMA(01093) fell 4.12%, with a trading turnover 857.3 Million HKD, and a year-to-date rose 10.4%.

Top Gainers&Losers

YOFC

HUA HONG SEMI

MONTAGE TECH

KNOWLEDGE ATLAS

DONGFANG ELEC

SBP GROUP

YANKUANG ENERGY

CNOOC

SKB BIO

Top 5 HK Stock Gainers/Losers (>100B) (4.8)

CSPC Pharmaceutical Group (SEHK:1093) has received regulatory approval for its Aprepitant Injection, aimed at preventing postoperative nausea and vomiting. The stock has shown strong performance with an 80.59% total shareholder return over the past year. Currently trading at HK$9.71, the company has a P/E ratio of 25.1x, which is below its estimated fair P/E of 28.4x but above the sector average of 15.4x. Analysts suggest the stock may be undervalued, with a DCF model indicating a future cash flow value of HK$17.67. Investors are advised to consider both the potential and risks involved.

Simplywall

CSPC Pharmaceutical Group (SEHK:1093) Valuation Check After Aprepitant Injection Approval

CSPC Pharmaceutical Group (CHJTF) was upgraded to a Hold rating by Bank of China with a price target of HK$9.10 on March 26, following a close of HK$8.16. UBS also assigned a Hold rating on March 25. Meanwhile, CMB International Securities maintained a Buy rating on the same day.

CSPC Pharmaceutical Group (CHJTF) was upgraded to a Hold Rating at Bank of China

Hong Kong stocks rose repeatedly, with the Hang Seng Index closing up 95 points at 24,951 points. Pharmaceutical stocks performed strongly, with CSPC PHARMA's share price rising nearly 14%. Several blue-chip companies announced their earnings, with CITIC Limited, Longfor, and Meituan seeing their share prices decline, while China Ping An and China Mobile's share prices increased. The total market turnover was HKD 263.081 billion

AASTOCKS

Harvest CNI Communication ETF

First Trust NYSE Arca Biotech Index Fd

"Hong Kong Stocks" Hang Seng Index closed up 95 points, pharmaceutical stocks led the rise, CSPC PHARMA surged nearly 14%

JP-CSPC@EC2611A(29257.HK)

CONCORD HC GP Proposes to Issue HKD68 Million Convertible Bonds to CSPC PHARMA

CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate

CSPC Innovation Posts Strong Revenue Growth but Wider Losses in Q1 2026

China’s drug makers are speeding up – will AI be their secret weapon?

CSPC Wins Shareholder Approval for Disposal of 30% Stake in Beijing Guoxin Huijin

Top 5 HK Stock Gainers/Losers (>100B) (4.8)

CSPC Pharmaceutical Group (SEHK:1093) Valuation Check After Aprepitant Injection Approval

CSPC Pharmaceutical Group (CHJTF) was upgraded to a Hold Rating at Bank of China

"Hong Kong Stocks" Hang Seng Index closed up 95 points, pharmaceutical stocks led the rise, CSPC PHARMA surged nearly 14%